Department of Anesthesiology and Pain Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
University of British Columbia, Vancouver, BC, Canada.
Can J Anaesth. 2019 Sep;66(9):1106-1112. doi: 10.1007/s12630-019-01389-6. Epub 2019 May 16.
The legislation Bill C-14 legalized medical assistance in dying (MAiD) in Canada. After thorough assessments of eligibility by two clinicians, Bill C-14 allows for both intravenous-assisted death by a clinician (euthanasia) and prescription of oral medication for self-administration (assisted suicide). Nevertheless, since inception in June 2016, intravenous euthanasia is the main form of delivery of assisted death in Canada. The reasons why oral MAiD is underutilized in Canada are multifactorial. Currently, there is no consensus on either the medications or the protocols for oral administration, nor a comprehensive understanding of the potential side effects and complications associated with different regimens. The quality of evidence for optimal MAiD medications is low, so any suggested recommendations can only be informed by the global but generally anecdotal experience. The challenges for implementing oral MAiD in Canada include a need to enhance clinician comfort in prescribing oral medications as an alternative to intravenous administration. The goals for ideal oral MAiD medications are 100% effectiveness and minimal side effects, while ensuring that the needed dose is both palatable and deliverable in a tolerable oral volume. The Netherlands has the most experience worldwide and barbiturates have emerged as the most common, efficacious, and tolerable agents by patients. Based on this global experience and the over-arching goals for oral MAiD, we recommend the use of a secobarbital suspension combined with antiemetic prophylaxis.
该立法法案 C-14 使医疗辅助自杀(MAiD)在加拿大合法化。在两位临床医生对资格进行彻底评估后,法案 C-14 允许临床医生通过静脉注射辅助死亡(安乐死)和开出处方让患者自行服用药物(协助自杀)。然而,自 2016 年 6 月实施以来,静脉内安乐死是加拿大实施协助自杀的主要形式。加拿大口服 MAiD 利用率低的原因是多方面的。目前,对于口服 MAiD 的药物和方案,既没有共识,也没有全面了解与不同方案相关的潜在副作用和并发症。最佳 MAiD 药物的证据质量较低,因此任何建议的建议只能通过全球但通常是轶事经验来告知。在加拿大实施口服 MAiD 的挑战包括需要增强临床医生开口服药物的舒适度,作为静脉注射的替代方案。理想的口服 MAiD 药物的目标是 100%的有效性和最小的副作用,同时确保所需剂量既可口又可在可耐受的口服量下给予。荷兰在全球范围内拥有最多的经验,巴比妥类药物已成为最常见、最有效和最耐受的药物。基于这一全球经验和口服 MAiD 的总体目标,我们建议使用戊巴比妥混悬液结合止吐预防。